NCT05601973
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05601973
Title AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)
Acronym AMAZE-lung
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ETOP IBCSG Partners Foundation
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD | ITA | GBR | FRA | ESP | CHE

Facility Status City State Zip Country Details
Chu Angers Angers France Details
Centre Hospitalier d'Avignon Avignon France Details
Centre Léon Bérard Lyon France Details
AO SM Misericorida Perugia Perugia Italy Details
Netherlands Cancer Institute (NKI) Amsterdam Netherlands Details
Hospital Universitario de A Coruña A Coruña Spain Details
Hospital Universitario Alicante Dr Balmis ISABIAL Alicante Spain Details
ICO Badalona Badalona Spain Details
Vall d´Hebron University Hospital VHIO Barcelona Spain Details
Hospital Universitario Basurto Bilbao Spain Details
Catalan Institute of Oncology L'Hospitalet de Llobregat Spain Details
Hospital Universitario Fundación Jiménez Díaz Madrid Spain Details
Hospital clínico universitario de Valladolid Valladolid Spain Details
Istituto Oncologico della Svizzera Italiana Bellinzona Switzerland Details
Universitätsklinik für Medizinische Onkologie, Inselspital Bern Switzerland Details
Hôpitaux universitaires de Genève (HUG) Geneva Switzerland Details
Kantonsspital St. Gallen Sankt Gallen Switzerland Details
The Royal Marsden NHS Foundation Trust London United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field